JTJean-Luc Teillaud

Jean-Luc Teillaud

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Jean-Luc Teillaud has a total of 86 co-authors. Here are the top co-authors by number of shared publications:

  • Sophie Sibéril

    Unité INSERM 255, IFR58, Université René Descartes-Paris 5, Université Pierre et Marie Curie-Paris 6, Centre de Recherches Biomédicales des Cordeliers, Paris, France

    5 shared publications
  • Marie-Caroline Dieu-Nosjean

    UMRS1135 Sorbonne University, INSERM U1135, Centre of Immunology and Microbial Infections (Cimi), Immune Microenvironment and Immunotherapy Team, Paris, France

    4 shared publications
  • Alexandra Desrames

    Université Paris Cité and Université des Antilles, Inserm, BIGR, F-75015 Paris, France

    3 shared publications
  • Arnaud Chêne

    INSERM UMR_1134, Paris, France Université Paris Diderot, Sorbonne Paris Cité, UMR_S1134, Paris, France Institut National de la Transfusion Sanguine, Paris, France Laboratory of Excellence GR-Ex, Paris, France

    3 shared publications
  • Benoit Gamain

    Sorbonne Université, INSERM, CNRS, Centre d’Immunologie et des Maladies Infectieuses, CIMI F-75013, Paris, France

    3 shared publications
  • Wolf Herman Fridman

    Centre de Recherche des Cordeliers, INSERM 1138, Sorbonne Université, Université de Paris

    3 shared publications

Latest Publications

  • Open Access

    médecine/sciences, être ou ne pas être, ou le pari gagnant d’une revue médicale et scientifique écrite dans la langue de Molière

    by Jean-Luc Teillaud

    Médecine/sciences (M/S), revue internationale dans le domaine de la recherche biologique, médicale et en santé

  • Open Access

    1985-2025, les Quarante Glorieuses de l’immunologie

    by Sophie Sibéril, Jean-Luc Teillaud

    Médecine/sciences (M/S), revue internationale dans le domaine de la recherche biologique, médicale et en santé

  • Exploring the Role of Tertiary Lymphoid Structures Using a Mouse Model of Bacteria-Infected Lungs

    by Jean-Luc Teillaud, Lucile Regard, Clémence Martin, Sophie Sibéril, Pierre-Régis Burgel

    Animal models can be helpful tools for deciphering the generation, maintenance, and role of tertiary lymphoid structures (TLS) during infections or tumor development. We describe here the establishment of a persistent lung infection in immune-competent mice by intratracheal instillation of agarose beads containing Pseudomonas aeruginosa or Staphylococcus aureus bacteria. After instillation, animals develop a chronic pulmonary infection, marked by the presence of TLS. This experimental setting allows the study of the function of TLS induced by bacteria encountered in patients with cystic fibrosis (CF) as P. aeruginosa and S. aureus are the two main bacterial strains that infect the bronchi of adult CF patients. Additionally, we describe also how to manipulate the immune response in these infected animals by targeting immune cells involved in TLS function. Overall, this approach makes it possible to explore the role of chronic inflammation in the induction and maintenance of TLS in infected tissues.


  • Top Cited Papers

    Tertiary lymphoid structures in anticancer immunity

    by Jean-Luc Teillaud, Ana Houel, Marylou Panouillot, Clémence Riffard, Marie-Caroline Dieu-Nosjean

    Tertiary lymphoid structures (TLS) are transient ectopic lymphoid aggregates where adaptive antitumour cellular and humoral responses can be elaborated. Initially described in non-small cell lung cancer as functional immune lymphoid structures associated with better clinical outcome, TLS have also been found in many other carcinomas, as well as melanomas and sarcomas, and associated with improved response to immunotherapy. The manipulation of TLS as a therapeutic strategy is now coming of age owing to the likely role of TLS in the improved survival of patients with cancer receiving immune checkpoint inhibitor treatment. TLS have also garnered considerable interest as a predictive biomarker of the response to antitumour therapies, including immune checkpoint blockade and, possibly, chemotherapy. However, several important questions still remain regarding the definition of TLS in terms of both their cellular composition and functions. Here, we summarize the current views on the composition of TLS at different stages of their development. We also discuss the role of B cells and T cells associated with TLS and their dialogue in mounting antibody and cellular antitumour responses, as well as some of the various mechanisms that negatively regulate antitumour activity of TLS. The prognostic value of TLS to the clinical outcome of patients with cancer and the relationship between TLS and the response to therapy are then addressed. Finally, we present some preclinical evidence that favours the idea that manipulating the formation and function of TLS could lead to a potent next-generation cancer immunotherapy.


  • Open Access

    Absence of sympathetic innervation hampers the generation of tertiary lymphoid structures upon acute lung inflammation

    by Clémence Riffard, Laïla Letaïef, Safa Azar, Armanda Casrouge, Isabelle Brunet, Jean-Luc Teillaud, Marie-Caroline Dieu-Nosjean

    Tertiary lymphoid structures (TLS) are lymphoid organs present in inflammatory non-lymphoid tissues. Studies have linked TLS to favorable outcomes for patients with cancers or infectious diseases, but the mechanisms underlying their formation are not fully understood. In particular, secondary lymphoid organs innervation raises the question of sympathetic nerve fibers involvement in TLS organogenesis. We established a model of pulmonary inflammation based on 5 daily intranasal instillations of lipopolysaccharide (LPS) in immunocompetent mice. In this setting, lung lymphoid aggregates formed transiently, evolving toward mature TLS and disappearing when inflammation resolved. Sympathetic nerve fibers were then depleted using 6-hydroxydopamine. TLS quantification by immunohistochemistry showed a decrease in LPS-induced TLS number and surface in denervated mouse lungs. Although a reduction in alveolar space was observed, it did not impair overall pulmonary content of transcripts encoding TNF-α, IL-1β and IFN-γ inflammation molecules whose expression was induced by LPS instillations. Immunofluorescence analysis of immune infiltrates in lungs of LPS-treated mice showed a drop in the proportion of CD23+ naive cells among CD19+ B220+ B cells in denervated mice whereas the proportion of other cell subsets remained unchanged. These data support the existence of neuroimmune crosstalk impacting lung TLS neogenesis and local naive B cell pool.


  • Open Access

    Clearing method adapted to FFPE tissues for 3D imaging of nerve fibers, B cells, and tertiary lymphoid structures

    by Safa Azar, Laïla Letaïef, Guy Malkinson, Sabrina Martin, Pierre Validire, Jean-Luc Teillaud, Marie-Caroline Dieu-Nosjean, Isabelle Brunet

    Summary: Biomedical samples are commonly used for histological examination after their inclusion in paraffin (Formalin-Fixed Paraffin-Embedded (FFPE) biopsy). However, they provide minimal information about the interactions between different tissue components such as blood vessels, nerves, and cellular aggregates. Here we present a modified iDISCO tissue-clearing method that we term miDISCO + . miDISCO + can be used for analyzing FFPE samples, requires the use of only one single FFPE sample, and allows to acquire a detailed image of the 3D tissue/organ architecture and the relevant cellular interactions. The addition of an antigen retrieval step to the protocol enables to use antibodies whose binding is sensitive to formalin fixation due to antigen masking. This method enabled us to detect CD20 + B cell follicles and to show that they are in close contact with TH + sympathetic nerve fibers in FFPE biopsies of human palatine tonsils, and to detect CD20 + B cells in lung tumors and observe their 3D organization within tertiary lymphoid structures. Thus, miDISCO + could be a potent tool for clinicians to refine diagnosis and to select optimal personalized treatment by giving an integrated 3D view of the tissue structures and cellular interactions in single FFPE samples.


  • Open Access

    Prix Nobel de physiologie ou médecine 2023 : Katalin Karikó et Drew Weissman

    by Marie-Caroline Dieu-Nosjean, Jean-Luc Teillaud

    Le 2 octobre 2023, le prix Nobel de physiologie ou médecine a été décerné à Katalin Karikó et Drew Weissman, tous deux professeurs à l’université de Pennsylvanie, pour leur « découverte concernant les modifications des nucléosides qui ont permis le développement de vaccins ARN efficaces contre le COVID-19 ». Le communiqué du comité Nobel indique que « grâce à leurs découvertes exceptionnelles qui ont changé radicalement notre compréhension des mécanismes par lesquels l’ARN messager interagit avec notre système immunitaire, ces deux lauréats ont contribué au développement, avec une rapidité sans précédent, d’un vaccin contre l’une des plus grandes menaces des temps modernes affectant la santé humaine ».


  • Open Access

    Le difficile art de la publication scientifique et médicale

    by Jean-Luc Teillaud

    Médecine/sciences (M/S), revue internationale dans le domaine de la recherche biologique, médicale et en santé


  • Open Access

    Expression and Purification of scFv2H7-P18F3, a Bi-Modular Fusion Protein (BMFP) Targeting Human CD20

    by Carine Brousse, Nathan Rainey, Alexandra Desrames, Jean- Teillaud, Benoît Gamain, Arnaud Chêne

    P18F3-based bi-modular fusion proteins (BMFPs), designed to re-direct pre-existing anti-Epstein-Barr virus (EBV) endogenous polyclonal antibodies towards defined target cells, demonstrated efficient biological activity in a mouse tumor model and could potentially represent a universal and versatile platform to develop novel therapeutics against a broad range of diseases. This protocol provides step-by-step instructions for expressing scFv2H7-P18F3, a BMFP targeting human CD20, in Escherichia coli (SHuffle®), and for purifying soluble proteins using a two-step process, namely immobilized metal affinity chromatography (IMAC) followed by size exclusion chromatography. This protocol can also be used for expression and purification of other BMFPs with alternative binding specificities.